Institutul Privat de Cercetari Melchisedec, pentru Boli Autoimune, Ereditare si Rare - IPCM

The department focuses on research that explores therapeutic strategies for schizophrenia, aiming to improve patient outcomes when standard antipsychotics fall short.

• Adjunctive use of valbenazine to reduce residual symptoms
• Safety and tolerability assessments in combination therapy
• Patient‑reported quality of life improvements

This work at Institutul Privat de Cercetari Melchisedec supports the broader goal of advancing behavioral health interventions for difficult‑to‑treat mental illness.

Investigators are evaluating novel approaches to manage core features of schizophrenia through targeted pharmacologic augmentation.

• Efficacy of adjunctive agents in treatment‑resistant populations
• Impact on negative and cognitive symptom domains
• Comparative analysis with placebo‑controlled groups

By conducting these trials in Craiova, the site contributes valuable data to European psychiatric research networks.